Local Recombinant DNA Oversight Mass Biotech Council Series Enforcement of the Cambridge Recombinant DNA Technology Ordinance Cambridge Biosafety Committee.

Slides:



Advertisements
Similar presentations
Biological Agents.
Advertisements

OVERVIEW OF INDUSTRIAL HYGIENE UNIVERSITY OF HOUSTON – DOWNTOWN CAMPUS.
THE NIH RECOMBINANT DNA 2002 GUIDELINES East Carolina University September 5, 2007.
Biosafety in Microbiologic and Biomedical Laboratories The University of Texas at Tyler IACUC Education and Training *Note: Content not specific to UT.
Biosafety and Facility Design
Safety Guidelines Illness and Injury Prevention Safety Guidelines Illness and Injury Prevention 2.01 Understand safety procedures 1.
© 2012 O’Brien & Gere # obgPresentation Are there Microbes Lurking? June 12, 2012 | State University of NY Paul W. Tranchell CIH, CSP, RBP Project Manager.
BIOLOGICAL HAZARDS RISK ASSESSMENT
Risk Assessment in Animal Biosafety ► Risk Assessment Factors  Pathogen/agent  Animal Model (species)  Procedures ► Proposed manipulations ► Assigned.
Outline Introduction to the National Institutes of Health Office of Biotechnology Activities History and Evolution of IBCs: Asilomar to the Present Overview.
THE NIH RECOMBINANT DNA 2002 GUIDELINES East Carolina University September 5, 2007.
BJH-WU Research Transition Washington University Environmental Health & Safety.
Biosafety Program Development Presented by: Lisa Wisser, CIH AIHCE - June 6, 2001.
Office of the Vice President for Research
6/2/2015 VEHS 1 Safety in the Workplace BME/CompE/EE/ME 297 Senior Design Seminar Robert Wheaton, MPH, CIH Vanderbilt University Director, Vanderbilt Environmental.
Principles and Practices of Biosafety Environmental Health and Safety San Diego State University.
The Select Agent Laboratory: at the intersection of research, preparedness and safety Nancy Connell,PhD Professor and Vice-chair for Research Department.
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Risk Group and Biosafety Level. Classification of Infective Agents by Risk Group Pathogenicity Pathogenicity Infectious Dose Infectious Dose Mode of Transmission.
WSU Biosafety Officer Lorraine McConnell
Institutional Biosafety Committee and Biological Use Authorization.
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
Environmental Health and Safety Radiation Control and Radiological Services.
Research and Biological Safety Office Environmental Health and Safety
O PERATING A BSL-3 F ACILITY IN K OREA T HE IVI E XPERIENCE INTERNATIONAL WORKSHOP ON ANTICIPATING BIOSECURITY CHALLENGES OF THE GLOBAL EXPANSION OF HIGH.
Safety Review and Approval Process for Research Proposals Robert Emery, DrPH, CHP, CIH, CBSP, CSP, CHMM, CPP, ARM Vice President for Safety, Health, Environment.
Foundation Training in Biological Safety. Module 4 Genetically modified organisms.
NC A&T STATE UNIVERSITY
RYERSON UNIVERSITY 1 1. ADMINISTRATION. RYERSON UNIVERSITY 2 Biological Safety Training – Certificate Holder and User Training BIOLOGICAL SAFETY at RYERSON.
LABORATORY BIOSAFETY FOCUS FORUM (LBFF). Delia Wolf Office of Regulatory Affairs & Research Compliance Dana Burns Leslie Howes Stanley Estime Jennifer.
Introduction to the MUSC Institutional Biosafety Committee (IBC) Registration Process Daniel Eisenman, PhD MUSC Biosafety Officer
Research Protocol Registration at WUStL Institutional Biological and Chemical Safety Committee/ Environmental Health and Safety Joe Kanabrocki Biological.
Safety, Health and Medical Services Division Ames Research Center These slides do not contain a complete summary of the Draft RFP. Therefore, please refer.
IACUC and IBC PROCESS. Office of Research Services Resource Center Building Room Kenneth Kratz, PhD –Director Staff: Nicole Barron – Pre-award.
CITI Biosafety Training Information Project
INSTITUTIONAL REVIEW OF BIOSAFETY RESEARCH Review of Institutional Biosafety Committee Application Form Robert J. Hashimoto The University of Kentucky.
Safety. Four Simple Questions What are the hazards? What are the hazards? What are the worst things that could happen? What are the worst things that.
Introduction to Biohazards: Risk Management
Discuss the major characteristics of the four Biosafety Levels. Define “Risk Group” and give an example of each. Discuss how Risk Groups are used in conjunction.
Safety organization and training. The biosafety officer and biosafety committee A safety policy, A safety manual, and Supporting programmes for their.
Biosafety and Bioethics Dr. Sarah bukhari Ass.Prof. pharmaceutical microbiology.
Research Compliance: An Overview of the Players and Issues Involved in Emory’s Research Compliance Programs.
Bioscience Safety Unit PROPERTY OF PIMA COUNTY JTED,
Tulane University - Office of Environmental Health & Safety (OEHS) Environmental Health & Safety Compliance Management System & Departmental Safety Representative.
Mid – Late 1970’s Emergence of recombinant DNA technology Concerns among both scientific community and general public:  Public health and safety  Environmental.
52 Table 1. Summary of Recommended Biosafety Levels for Infectious Agents. Biosafety Level Agents Practices Safety Equipment (Primary Barriers) Facilities.
Responsible Care® Basic Awareness 1. DISCUSSION POINTS 2 WHAT IS RESPONSIBLE CARE®? HOW DOES RESPONSIBLE CARE® ADD VALUE? WHAT CAN YOU DO TO SUPPORT RESPONSIBLE.
LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER NEW ORLEANS.
Laboratory Safety Deona Willes, MPH Deputy Director Office of Environmental Health and Safety I Environmental.
R EGULATORY A GENCIES What are regulatory issues? Types of agencies How they affect you Top 10 regulatory issues.
MAY 21, 2014 Watertown Board of Health FY15 Budget Hearing.
Objectives  Define risk assessment as it relates to biosafety  Understand the risk assessment process and how to implement it  Discuss risk factors.
Ratification of BWC BWC Expert Group, Republic of Korea Compendium of National Activities in Korea: Measures to Improve Biosafety and Biosecurity Hei Chan.
Institutional Biosafety Committee Member Training October 2013.
NIH Guidelines for Research Involving rDNA Molecules (NIH Guidelines) and Institutional Biosafety Committees.
FY02 ASA Presentation Provide Workplace Safety Presented by: Deborah E. Wilson, DrPH, SM, CBSP Occupational Safety & Health Branch Division of Safety,
The IBC is: The Institutional Biosafety Committee (aka Biohazards Committee)
THE NIH RECOMBINANT DNA GUIDELINES Bob Hashimoto The University of Louisville April 2001.
Laboratory Safety 1 Navigating the University: Laboratory Safety James Gibson, PhD, MPH Executive Director, Office of Environmental Health & Safety Descanso.
Chapter 5 Environmental Health and Safety. Objectives 1.Understand the importance of effective EHS processes in biomanufacturing 2.Describe EHS regulatory.
Regulatory Agencies What are regulatory issues? Types of agencies How they affect you Top 10 regulatory issues.
Stanford University Dual Use Research of Concern in the Life Sciences
Overview of the NIH Guidelines for Research Involving Recombinant DNA Molecules This is an edited combination of Haverford College’s IBC training materials.
ROLE OF THE INSTITUTIONAL BIOSAFETY COMMITTEE
CHAPTER 15 Biological Hazards.
Biosafety Overview for Laboratories
Working with Biological Hazards
IACUC Occupational Health & Safety Programs
ROLE OF KEPHIS IN SAFE HANDLING, TRANSFER AND USE OF GMOS.
Biosafety Principles: Separation, Seclusion & Containment
Presentation transcript:

Local Recombinant DNA Oversight Mass Biotech Council Series Enforcement of the Cambridge Recombinant DNA Technology Ordinance Cambridge Biosafety Committee and Cambridge Public Health Department July 9th, 2009

Local Recombinant DNA Oversight The Debate 1970s and the “Gene Scare” Asilomar Conference (1975) Cambridge debates gene splicing NIH develops biosafety standards Recombinant DNA Technology ordinance Other communities weigh in Amendments & Enforcement

Local Recombinant DNA Oversight Public Perception of Risk Public health alarm has dissipated vs. 1970s Biotech as a clean, low-impact industry New focus of public concern: Biological/Chemical/Radiological terrorism Pandemic flu CDC-funded biocontainment labs (e.g. BU lab) Public concern has also shifted to the applications of genetic technology GM foods Gene therapy Pharmaceutical safety, efficacy and value

Local Recombinant DNA Oversight Benefits of Cambridge/NIH Rules Labs commit to public/worker safety via Institutional Biosafety Committees (IBCs): safe lab practices, training, containment Companies and researchers get more predictable regulatory oversight; goodwill Public gains accountability and transparency Public participation on these IBCs improves their public credibility and informs residents

Local Recombinant DNA Oversight RDNA Permit Holder Responsibilities Ensure compliance with NIH Guidelines and local rDNA regulation Establish an IBC with full membership Appoint a Biosafety Officer (BSO) Ensure IBC has expertise in all reviewed work and that members are trained Establish a medical surveillance program Report accidents to the NIH and local BOH Submit Annual Reports to NIH & BOH

Local Recombinant DNA Oversight Biological Safety … is achieved through a combination of containment principles operating at different levels: Biological Containment Environmental stability, growth factors, routes of infection, attenuated strains, media requirements Primary Containment Safety cabinets, good microbiological practices, PPE Secondary Containment Barriers, decontamination, air flow, gas-tight (BSL3) 6

Local Recombinant DNA Oversight Biosafety Levels … describe a hierarchy of procedures, practices, equipment and lab design which achieve containment for the organism in question and the procedures to be used Biosafety levels are ranked from 1- 4, BSL-4 being the most stringent. Cambridge does not allow BSL-4 labs under the rDNA ordinance. Biosafety level assignment for a project is the result of a Comprehensive Risk Assessment based on procedures and the Risk Group for that agent ….

Local Recombinant DNA Oversight Risk Group Levels Risk Group 1: Agents that are not associated with disease in healthy adult humans Risk Group 2: Agents that are associated with human disease which is rarely serious and for which preventive or therapeutic interventions are often available Risk Group 3: Agents associated with serious or lethal human disease for which preventive or therapeutic interventions may be available (high worker risk but low community risk) Risk Group 4: Agents likely to cause serious lethal human disease for which preventive or therapeutic interventions are not usually available (high worker & community risk)

Pathogenicity Infectious dose Concentration Environmental Stability Transmission route Host Range Training & Skill Level Vaccination Availability Population Risk Factors Medical Interventions Disease Outcomes Local Recombinant DNA Oversight Lab Worker vs. Community Risk

Local Recombinant DNA Oversight Local Enforcement Agencies Cambridge Biosafety Committee (CBC) CBC Meetings IBC Representatives Presentation to CBC Laboratory Site Visits Fire Department & LEPC Chemical hygiene plans, flammables, hazmat response, advanced 911 compatibility

Local Recombinant DNA Oversight Required Presentation to the CBC Mission of Research Overview of rDNA Procedures & Vectors Floor Plans: BL level & Access Control Employee Medical Surveillance Permits received and pending (local, state) Service Contracts: Bio, Chem, Rad, Pests Submit Biosafety Manual & IBC Reps

Local Recombinant DNA Oversight Laboratory Site Visit General Lab Hygiene Wastewater Treatment/Backflow Prevention Signage Access Controls HVAC Systems/Air Balance/Filtration Biological/Chemical Waste Systems Ergonomics and Safety